Taro said that its meloxicam tablets product is bioequivalent to Boehringer Ingelheim’s Mobic tablets. According to industry sources, branded and generic meloxicam tablet products had US sales of approximately $105 million in the third quarter of 2006.
Taro also reported that it has received tentative approval from the FDA for its generic cetirizine hydrochloride syrup. The FDA is saod to have determined that Taro’s cetirizine syrup is safe and effective for use when compared with the reference listed drug product, Zyrtec Syrup manufactured by Pfizer.
Zyrtec Syrup is a prescription product used for treating allergic rhinitis and chronic urticaria.